Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
74.12 USD | -1.03% | +3.47% | -7.02% |
04-30 | North American Morning Briefing : More Earnings -2- | DJ |
04-29 | Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.02% | 3.56B | |
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-17.13% | 31.47B | |
+53.99% | 25.24B | |
-13.85% | 15.82B | |
-9.12% | 11.96B | |
-16.20% | 11.89B | |
-42.56% | 11.61B | |
+4.42% | 8.84B |
- Stock Market
- Equities
- AXSM Stock
- News Axsome Therapeutics, Inc.
- Morgan Stanley Adjusts Price Target on Axsome Therapeutics to $86 From $73, Maintains Equal-Weight Rating